Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexStudies have indicated that Celebrex danger may increase a patient’s risk of suffering serious and life threatening side effects including heart attack and stroke. Celebrex is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) approved to treat the pain associated with osteoarthritis, rheumatoid arthritis, menstrual cramps, and other chronic pain conditions. Celebrex is the only COX-2 NSAID to gain FDA approval for the treatment of adenomatous polyposis.
A recent study has shown that patients who take this medication may be in serious Celebrex danger. The National Cancer Institute discovered this Celebrex danger while studying the effects of Celebrex on the formation of colon polyps. This clinical trial was designed as a three year study to measure the long term colorectal effects of Celebrex as compared to a placebo, or dummy pill. This clinical trial was sponsored in part by Pfizer, the makers of this top selling prescription medication.
The Celebrex danger that was discovered prompted researchers to discontinue the study. Researchers found that patients taking four hundred milligrams of Celebrex daily were 2.5 times more likely to suffer a heart attack or stoke as those in the control group. The Celebrex danger was even greater for patients taking a higher dose of this pain reliever. Trial participants who had taken eight hundred milligrams of Celebrex each day were found to be 3.4 times more likely to suffer a serious heart attack or stroke.
The announcement of this Celebrex danger follows the recall of a similar COX-2 NSAID called Vioxx. Vioxx was pulled off the shelves in September 2004, after clinical research found that patients taking Vioxx for eighteen months were twice as likely to suffer an adverse cardiovascular event as compared to the general population. If the Celebrex study findings are substantiated, the Celebrex danger posed to patients may be even greater than the danger associated with Vioxx.
Despite knowledge of significant Celebrex danger, Pfizer has made no indication that they plan to pull Celebrex off the market. Pfizer consistently argues that their product is safe despite clinical evidence to the contrary. As a result of the December 2004 announcement about cardiovascular Celebrex danger, Pfizer has been subject to harsh criticism and has been ordered by the FDA to restrict their Celebrex marketing.
In January 2005 the FDA ordered Pfizer to pull all commercial ads for Celebrex until Celebrex danger could be further evaluated. Top researchers and medical professionals all over the nation have also responded to the Celebrex danger warnings by urging doctors and patients to look for alternative treatments. Since the announcement of the Celebrex warning, new sales of this pain killer have dropped more than fifty-six percent.
The FDA announced in early 2005 their plans to conduct further investigation of this Celebrex danger in order to determine whether further regulatory action is appropriate.
If you are concerned about Celebrex danger, you may wish to contact a qualified and professional attorney.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...